iCeutica
Developer of a proprietary fine-particle platform that reduces drug particle size to submicron dimensions to improve oral bioavailability, reduce pharmacokinetic variability and enable reformulation of marketed and development-stage drugs. Provides formulation development, analytical methods, prototyping and scale-up services and pursues partnered licensing and internal product development in pain/inflammation, oncology and respiratory disease.
Industries
Nr. of Employees
small (1-50)
iCeutica
116 Village Blvd., Suite 200, Princeton, NJ 08540, USA
Products
Pipeline of product candidates using submicron particle technology
Proprietary and partnered candidates across pain & inflammation, oncology and respiratory disease developed using submicron particle formulation approaches to improve PK and clinical performance.
Pipeline of product candidates using submicron particle technology
Proprietary and partnered candidates across pain & inflammation, oncology and respiratory disease developed using submicron particle formulation approaches to improve PK and clinical performance.
Services
Formulation and prototyping of oral and inhaled products using submicron particle technology.
Analytical support and method development to characterize formulations and support PK/bioavailability studies.
Preparation of clinical trial material from concept through to dosing forms for Phase 1–3 studies.
Scale-up of manufacturing processes and support for commercialization and partner licensing.
Formulation and prototyping of oral and inhaled products using submicron particle technology.
Analytical support and method development to characterize formulations and support PK/bioavailability studies.
Preparation of clinical trial material from concept through to dosing forms for Phase 1–3 studies.
Scale-up of manufacturing processes and support for commercialization and partner licensing.
Expertise Areas
- Particle engineering and submicron formulation
- Formulation development for oral and inhaled dosage forms
- Clinical trial design and execution for reformulated drugs
- Pharmacokinetics and bioavailability optimization
Key Technologies
- Dry milling for particle size reduction
- Submicron particle-based drug delivery
- Oral solid dosage formulation (tablet and capsule prototyping)
- Inhalation formulation engineering
News & Updates
U.S. patent (No. 8,808,751) awarded covering a dry-milling method for producing submicron-sized drug particles.
Partnered reformulations using the submicron particle platform received FDA approvals and U.S. market launches (partner approvals documented in 2013–2014 announcements).
Announcement of a second FDA approval for a partner product developed using the submicron particle platform.
U.S. patent (No. 8,808,751) awarded covering a dry-milling method for producing submicron-sized drug particles.
Partnered reformulations using the submicron particle platform received FDA approvals and U.S. market launches (partner approvals documented in 2013–2014 announcements).
Announcement of a second FDA approval for a partner product developed using the submicron particle platform.